natgillin/translations-raw huggingface dataset:
After 16 weeks of therapy, patients who achieved at least a PASI 75 response (PASI score improvement of at least 75% relative to baseline), entered period B and received open-label 40 mg Humira every other week.
Po 16 tednih zdravljenja so bolniki, ki so dosegli odziv PASI vsaj 75 (izboljšanje ocene PASI za vsaj 75 % glede na izhodišče), vstopili v obdobje B, med katerim so odprto dobivali 40 mg zdravila Humira vsak drugi teden.
After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) ≥ 30 % (p = 0.02).
Po 16 tednih zdravljenja je bila razlika v deležu odziva statistično značilna v prid metotreksata po opredelitvi izboljšanja (DOI - Definition of Improvement) za JRA ≥ 0% (p = 0,02).
After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) ≥ 30 % (p = 0.02).
Po 16 tednih zdravljenja je bila razlika v deležu odziva statistično značilna v prid metotreksata po opredelitvi izboljšanja (DOI - Definition of Improvement) za JRA ≥ 30 % (p = 0,02).
After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) ≥ 30 % (p = 0.02).
Po 16 tednih zdravljenja je bila razlika v deležu odziva statistično značilna v prid metotreksata po opredelitvi izboljšanja (DOI - Definition of Improvement) za JRA ≥ 30% (p = 0,02).
After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) ≥30% (p=0.02).
Po 16 tednih zdravljenja je bila razlika v deležu odziva statistično značilna v prid metotreksata po opredelitvi izboljšanja (DOI - Definition of Improvement) za JRA ≥ 30 % (p = 0,02).
After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) 30% (p=0.02).
Po 16 tednih zdravljenja je bila razlika v deležu odziva statistično značilna v prid metotreksata po opredelitvi izboljšanja (DOI - Definition of Improvement) za JRA ≥ 30 % (p = 0,02).
After 16 weeks, patients treated with Adempas could walk on average 46 metres further in six minutes than patients taking placebo.
Po 16 tednih so lahko bolniki, ki so jih zdravili z zdravilom Adempas, v šestih minutah v povprečju prehodili 46 metrov več kot bolniki, ki so jemali placebo.
After 16 weeks, the mean oxygen saturation was increased in the bosentan group by 1.0% (95% CI –0.7%–2.8%) as compared to the placebo group (n = 17 patients), showing that bosentan did not worsen hypoxaemia.
Po 16 tednih je bila v skupini, ki je prejemala bosentan, povprečna saturacija s kisikom za 1,0 % (95-% IZ–0,7 %–2,8 %) večja kot v skupini, ki je prejemala placebo (n = 17 bolnikov), kar je dokazalo, da bosentan ni poslabšal hipoksemije.
After 16 weeks’ treatment, there were significant improvements from baseline in exercise capacity: the mean increase in 6- minute walk distance was 91.4 metres from 332.6 metres on average at baseline (p < 0.001).
Po 16 tednih so opazili pomembna izboljšanja od izhodiščne zmogljivosti za telesno vadbo: povprečno povečanje razdalje, prehojene v 6-minutnem preizkusu s hojo: 91,4 metra s povprečne izhodiščne razdalje 332,6 metra (p < 0,001).
After 168 weeks, 16% (7/45) of the tenofovir disoproxil fumarate group, 4% (2/45) of the emtricitabine plus tenofovir disoproxil fumarate group, and 14% (3/22) of the entecavir group experienced tolerability failure.
Po 168 tednih je 16% (7/45) v skupini z dizoproksiltenofovirijevim fumaratom, 4% (2/45) v skupini z emtricitabinom in dizoproksiltenofovirijevim fumaratom in 14% (3/22) v skupini z entekavirjem doživelo tolerančno napako.
After 18 months of Cerdelga treatment, the mean (SD) lumbar spine bone mineral density (BMD) T- score increased from -1.06 (0.82) (n=17), to -0.91 (0.88) (n=15).
Po 18 mesecih zdravljenja z zdravilom Cerdelga se je povprečna (standardni odklon [standard deviation, SD]) vrednost T mineralne gostote kosti (bone mineral density, BMD) za ledveno hrbtenico dvignila iz -1,06 (0,82) (n=17) na -0,91 (0,88) (n=15).
After 2 doses of 0.5 ml
Po 2 odmerkih po 0,5 ml
After 2 hours, check the injection site for redness, swelling, or tenderness.
Po 2 urah preverite, ali je mesto injiciranja pordelo, oteklo ali občutljivo.
After 2 months of treatment more than 40% of the patients who were taking Deltyba no longer had the bacteria in their sputum compared with 30% of the patients who were taking placebo.
Po dveh mesecih zdravljenja več kot 40 % bolnikov, zdravljenih z zdravilom Deltyba, ni imelo več bakterij v izpljunku, v primerjavi s 30 % bolnikov, ki so prejemali placebo.
After 2 weeks the treatment will be reassessed.
Po 2 tednih bo učinke zdravljenja ponovno ocenil.
After 2 years of treatment, patients should be re- informed about the risks of TYSABRI, especially the increased risk of Progressive Multifocal Leukoencephalopathy (PML), and should be instructed together with their caregivers on early signs and symptoms of PML.
Po 2 letih zdravljenja je treba bolnike ponovno informirati o tveganjih v zvezi z zdravilom TYSABRI, posebej še o povečanem tveganju progresivne multifokalne levkoencefalopatije (PML), skupaj z njihovimi skrbniki pa jih je treba tudi poučiti o zgodnjih znakih in simptomih PML.
After 2-4 weeks of treatment, patients should be re-assessed in order to evaluate the benefit and tolerability of the therapy.
Po 2- tednih zdravljenja je treba bolnice ponovno pregledati, da ovrednotimo učinkovitost in prenosljivost zdravljenja.
After 20 units (about 100 ml/kg) of PRBC
po 20 enotah (približno 100 ml/kg)
After 24 weeks of Revestive treatment, patients showed small overall increase in C-reactive protein of approximately 1.5 mg/l on average.
Po 24 tednih zdravljenja z zdravilom Revestive so pri bolnikih ugotovili blago zvišano koncentracijo C-reaktivnega proteina, v povprečju za približno 1,5 mg/l.
After 24 weeks of treatment the mean ( Standard Deviation [SD]) maximum plasma concentration (Cmax) was 2,357 (± 1,560) ng/ml and the mean ( SD) area under the plasma concentration-time curve (AUC0-t) was 5,860 ( 4,184) h  ng/ml.
Po 24 tednih zdravljenja je bila povprečna ( standardni odklon [SD – »standard deviation«]) najvišja plazemska koncentracija 2,357 (1,560) ng/ml in povprečna (SD) površina pod plazemsko koncentracijsko krivuljo (AUC0-t) 5,860 (4,184) h x ng/ml.
After 24 weeks of treatment, the primary endpoint of mean change from baseline in HbA1c was -1.83% in the combination group versus -0.96% in the pioglitazone group (p< 0.0001) and -0.99% in the metformin group (p< 0.0001).
Po 24 tednih zdravljenja je bila primarna končna točka povprečne spremembe od izhodišča za HbA1c -1,83 % v skupini s kombinacijo v primerjavi z -0,96% v skupini s pioglitazonom (p < 0,0001) in -0,99% v skupini z metforminom (p < 0,0001).
After 24 weeks, 59% of the patients taking Intelence (353 out of 599) had a viral load below 50 copies/ml, compared with 41% of those taking placebo (248 out of 604).
Po 24 tednih je bila pri 59 % (353 od 599) bolnikov, ki so jemali zdravilo Intelence, virusna obremenitev pod 50 kopij/ml v primerjavi z 41 % (248 od 604)bolnikov, ki so jemali placebo.
After 240 weeks of treatment, 117 of 141 subjects (83%) randomised to tenofovir disoproxil fumarate had HBV DNA < 400 copies/ml, and 51 of 79 subjects (65%) had ALT normalisation.
Po 240. tednih zdravljenja je imelo 117 od 141 bolnikov (83%), randomiziranih na dizoproksiltenofovirijev fumarat, HBV DNA < 400 kopij/ml in 51 od 79 bolnikov (65%) je imelo normalizacijo ALT.
After 28 weeks of treatment following the dosing guideline outlined in section 4.2, the mean reduction in HbA1c was 2.8% with NovoMix 30 (mean at baseline = 9.7%).
Po 28 tednih zdravljenja v skladu s smernicami za odmerjanje, opisanimi v poglavju 4.2, je bilo povprečno znižanje HbA1c z zdravilom NovoMix 30 2,8 % (povprečna izhodiščna vrednost je bila 9,7 %).
After 2–4 weeks, the dose should be titrated to 500 mg twice daily and, according to the patient’s response, further titrated to a recommended maximum dose of 750 mg twice daily (see section 5.1).
Po 2–4 tednih je treba odmerek titrirati na 500 mg dvakrat na dan in potem, glede na bolnikov odziv, do priporočenega največjega odmerka 750 mg dvakrat na dan, (glejte poglavje 5.1).
After 3 months, your doctor may discontinue either Rapamune or ciclosporin, as it is not recommended that these medicines be taken together beyond this period.
Po 3 mesecih vam lahko zdravnik ukine bodisi zdravilo Rapamune bodisi ciklosporin, ker ni priporočljivo, da bi ta zdravila jemali skupaj več kot 3 mesece.
After 3 weeks from the 2nd vaccination (day 43) all age groups (i.e.
Po 3 tednih od 2. cepljenja (43. dan) so vse starostne skupine (tj.
After 3 weeks, subjects in both the sapropterin and placebo treatment groups were continued on their phenylalanine-restricted diets and dietary phenylalanine intake was increased or decreased using standardized phenylalanine supplements with a goal to maintain blood phenylalanine levels at
Po treh tednih so osebe v obeh skupinah (v tisti, ki je prejemala sapropterin in tisti, ki je prejemala placebo) nadaljevale s svojo prehrano z omejeno količino fenilalanina, vnos fenilalanina s hrano pa se je povečeval ali zmanjševal z uporabo standardiziranih fenilalaninskih dodatkov, z namenom, da bi raven fenilalanina v krvi vzdrževali na vrednosti < 360 µmol/l.
After 30 minutes, if pieces of the tablet remain, they may be swallowed with a glass of water.
Po 30 minutah lahko morebitne ostanke tablete pogoltnete s kozarcem vode.
After 30 weeks, patients taking Numient had their symptoms improve by an average of between 11.7 and 14.9 points (depending on dose) on a standard symptom scale (Unified Parkinson’s Disease Rating Scale, UPDRS Part II and Part III).
Po 30 tednih so se pri bolnikih, ki so prejemali zdravilo Numient, simptomi v povprečju izboljšali za 11,7 do 14,9 točke (odvisno od odmerka) na standardni lestvici za oceno simptomov (enotna ocenjevalna lestvica za Parkinsonovo bolezen (UPDRS), II. del in III. del).
After 32 weeks or at disease flare, patients were eligible to enroll into the open label extension phase.
Po 32 tednih ali v primeru zagona bolezni so bili bolniki primerni za vključitev v odprto podaljšano fazo.
After 4 hours of NexoBrid treatment, the occlusive dressing must be removed using aseptic techniques.
Po 4 urah zdravljenja z zdravilom NexoBrid morate okluzivno oblogo odstraniti z aseptično tehniko.
After 4 weeks of bosentan 62.5 mg twice daily, the maintenance dose studied in both these studies was 125 mg twice daily.
Po 4 tednih jemanja bosentana v odmerku 62,5 mg dvakrat na dan je bil vzdrževalni odmerek, preučevani v teh študijah, 125 mg dvakrat na dan.
After 4 weeks of bosentan 62.5 mg twice daily, the maintenance dose studied in both these studies was 125 mg twice daily.
Po 4 tednih jemanja bosentana v odmerku 62,5 mg dvakrat na dan so bili vzdrževalni odmerek, preučevani v teh študijah, 125 mg dvakrat na dan.
After 4 weeks, your doctor may raise your dose to two tablets a day.
Po 4 tednih vam zdravnik lahko odmerek poveča na dve tableti na dan.
After 44 weeks of starting treatment by injection under the skin, 53% of patients on Stelara every 8 weeks and 49% of patients on Stelara every 12 weeks had a significant reduction in symptoms of Crohn’s disease, compared with 36% of patients on placebo.
Po 44 tednih prejemanja injekcij v podkožje so se simptomi Crohnove bolezni bistveno zmanjšali pri 53 % bolnikov, ki so prejemali zdravilo Stelara vsakih 8 tednov, in pri 49 % bolnikov, ki so zdravilo Stelara prejemali vsakih 12 tednov, v primerjavi s 36 % bolnikov, ki so prejemali placebo.
After 48 weeks
po 48 tednih
After 48 weeks all patients were adjusted to the recommended dose 1.0 mg/kg/day.
Po 48. tednih so pri vseh bolnikih odmerek prilagodili na priporočeni odmerek 1,0 mg/kg/dan.
After 48 weeks of treatment with Kaletra, efavirenz and nucleoside reverse transcriptase inhibitors, plasma HIV RNA  400 copies/ml was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with
Po 48 tednih zdravljenja z zdravilom Kaletra, efavirenzem in nukleozidnimi zaviralci reverzne transkriptaze so HIV RNA v plazmi  400 izvodov/ml ugotovili pri 93% (25/27), 73% (11/15), in 25% (2/8) bolnikov z
After 48 weeks of treatment with lopinavir/ritonavir, efavirenz and nucleoside reverse transcriptase inhibitors, plasma HIV RNA ≤ 400 copies/ml was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with < 10-fold, 10 to 40-fold, and > 40-fold reduced susceptibility to lopinavir at baseline, respectively.
Po 48 tednih zdravljenja z lopinavirjem/ritonavirjem, efavirenzem in nukleozidnimi zaviralci reverzne transkriptaze so HIV RNA v plazmi ≤ 400 izvodov/ml ugotovili pri 93% (25/27), 73% (11/15), in 25% (2/8) bolnikov z < 10-krat, 10- do 40-krat oz. > 40-krat zmanjšano izhodiščno občutljivostjo za lopinavir.
After 48 weeks, 69% of the treatment-naïve adults taking ritonavir-boosted Telzir (221 out of 322) and 68% of those taking nelfinavir (221 out of 327) had viral loads below 400 copies/ml.
Po 48 tednih je imelo 69 % bolnikov, ki se zaradi okužbe z virusom HIV še niso zdravili in so jemali z ritonavirjem ojačano zdravilo Telzir (221 od 322), in 68 % bolnikov, ki so jemali nelfinavir (221 od 327) virusno obremenitev pod 400 kopij/ml.
After 48 weeks, 71% of the HBeAg-negative and 67% of HBeAg-positive patients taking Viread had a complete response to treatment, compared with 49% and 12%, respectively, of the patients taking adefovir dipivoxil.
Po 48 tednih se je 71 % bolnikov, ki so bili „HBeAg negativni“, in 67 % tistih, ki so bili „HBeAg pozitivni“, popolnoma odzvalo na zdravljenje z zdravilom Viread v primerjavi z 49 % oziroma 12 % bolnikov, ki so jemali adefovirdipivoksil.
After 48 weeks, around 59% of patients treated with Vitekta (207 out of 351) responded to treatment compared with around 58% of patients treated with raltegravir (203 out of 351).
Po 48 tednih se je na zdravljenje odzvalo približno 59 % (207 od 351) bolnikov, zdravljenih z zdravilom Vitekta, v primerjavi z 58 % (203 od 351) bolnikov, zdravljenih z raltegravirjem.
After 48 weeks, around 88% of patients treated with Stribild (305 out of 348) responded to treatment compared with around 84% of patients treated with the comparator medicine (296 out of 352).
Po 48 tednih se je približno 88 % bolnikov, ki so prejeli zdravljenje z zdravilom Stribild (305 od 348), odzvalo na zdravljenje v primerjavi s približno 84 % bolnikov, ki so prejemali primerjalno zdravilo (296 od 352).
After 48 weeks, around 90% of patients treated with Stribild (316 out of 353) responded to treatment compared with around 87% of patients treated with the comparator treatment (308 out of 355).
Po 48 tednih se je približno 90 % bolnikov, ki so prejeli zdravljenje z zdravilom Stribild (316 od 353), odzvalo na zdravljenje v primerjavi s približno 87 % bolnikov, ki so prejemali primerjalno zdravljenje (308 od 355).
After 5 minutes, press the plunger all the way down, back into the syringe.
Po 5 minutah spet potisnite bat v brizgi do konca navzdol.
After 5 years of receiving Bonviva, please consult with your doctor whether you should continue to receive Bonviva.
Po petih letih uporabe zdravila Bonviva se, prosimo, posvetujte z zdravnikom glede nadaljevanja jemanja zdravila Bonviva.
After 52 weeks, the saxagliptin and glipizide groups had similar mean reductions from baseline in HbA1c in the per-protocol analysis (-0.7% vs. –0.8%, respectively, mean baseline HbA1c of 7.5% for both groups).
Po 52 tednih so v analizi skupin po protokolu s saksagliptinom in glipizidom ugotovili podobno povprečno zmanjšanje vrednosti HbA1c v primerjavi z izhodiščem (-0,7 % v prvi skupini v primerjavi z -0,8 % v drugi skupini, povprečni izhodiščni HbA1c je bil v obeh skupinah 7,5 %).
After 56 weeks of treatment in subjects with type 2 diabetes (NB-304), naltrexone / bupropion exhibited improvements in glycaemic control parameters compared to placebo (Table 4).
Po 56 tednih zdravljenja preiskovancev s sladkorno boleznijo tipa 2 (NB-304) so pri uporabi naltreksona/bupropiona ugotovili izboljšave pri parametrih glikemičnega nadzora v primerjavi z uporabo placeba (Preglednica 4).
After 6 months of ocular instillation of IKERVIS once per day, 327 patients had values below the lower limit of detection (0.050 ng/mL) and 35 patients were below the lower limit of quantification (0.100 ng/mL).
Po 6. mesecih vkapavanja zdravila IKERVIS v oko enkrat na dan je imelo 327 bolnikov vrednosti pod spodnjo mejo detekcije (0,050 ng/ml) in 35 bolnikov je bilo pod spodnjo mejo kvantifikacije (0,100 ng/ml).
After 6 months, patients in the sham-control arms switched to 0.5 mg ranibizumab
Po mesecu so bolniki v skupini s placebom prešli na zdravljenje z ranibizumabom v odmerku 0,5 mg.
After 7 and a half years of treatment (including the 72-week parent study), a substantial and sustained decrease in various B cell subsets was observed leading to 87% median reduction in naïve B cells, 67% in memory B cells, 99% in activated B cells, and 92% median reduction in plasma cells after more than 7 years of treatment.
Po sedmih letih in pol (vključno z 72 tedni v matični študiji) so opažali bistveno in dolgotrajno zmanjšanje števila različnih podskupin celic B, ki je povzročilo 87-odstotno mediano zmanjšanje števila naivnih celic B, 67-odstotno spominskih celic B, 99-odstotno aktiviranih celic B in 92-odstotno mediano zmanjšanje števila plazmatk po več kot 7 letih zdravljenja.
After 7 days, the dose is increased to the recommended dose of 240 mg twice a day.
Po 7 dneh se odmerek zviša na priporočeni odmerek 240 mg dvakrat na dan.
After 7 days, the recommended dose of Invirase is 1,000 mg two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents.
Po sedmih dneh znaša priporočeni odmerek zdravila Invirase 1 000 mg dvakrat na dan skupaj s 100-miligramskim ritonavirjem dvakrat na dan v kombinaciji z drugimi protiretrovirusnimi zdravili.
After 7 days, the recommended dose of Invirase is 1000 mg two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents.
Po 7 dneh je priporočeni odmerek zdravila Invirase 1000 mg dvakrat na dan s 100 mg ritonavirja dva krat na dan v kombinaciji z drugimi protiretrovirusnimi zdravili.
After 7 years, the VTE rate per 1,000 women-years was 2.06 in the bazedoxifene 20 mg group and 1.36 in the placebo group.
Po 7 letih je bil delež VTE na 1.000 žensk-let 2,06 v skupini, ki je prejemala 20 mg bazedoksifena, in 1,36 v skupini, ki je prejemala placebo.
After 72 weeks of blinded randomized treatment, each subject could switch to open-label tenofovir disoproxil fumarate treatment up to week 192.
Po 72 tednih slepega randomiziranega zdravljenja so lahko bolniki prešli na odprto zdravljenje z dizoproksiltenofovirijevim fumaratom do 192. tedna.
After 8 weeks of treatment, each of the combinations was statistically significantly superior to both amlodipine monotherapy doses in reducing systolic and diastolic blood pressures (13.6/9.4 mmHg,
Po 8 tednih zdravljenja sta obe kombinaciji statistično značilno učinkoviteje znižali sistolični in diastolični krvni tlak kot odmerka amlodipina (-13,6/-9,4 mm Hg,
After 8 weeks of treatment, each of the combinations was statistically significantly superior to both amlodipine monotherapy doses in reducing systolic and diastolic blood pressures (13.6/9.4 mmHg,
Po 8 tednih zdravljenja sta obe kombinaciji statistično značilno učinkoviteje znižali sistolični in diastolični krvni tlak kot odmerka amlodipina (-13,6/-9,4 mm Hg, -15,0/-10,6 mm Hg pri 40 mg/5 mg, 80 mg/5 mg v primerjavi z -6,2/-5,7 mm Hg,
After 96 weeks of Atripla treatment, HIV-1 RNA plasma concentrations remained
Po 96 tednih zdravljenja z zdravilom Atripla so bile
After a 30 second rest period, repeat the penile modeling technique for a total of 3 modeling attempts at 30 seconds for each attempt.
Nato ga sprostite in počakajte 30 sekund, preden tehniko modeliranja penisa ponovite, in sicer skupaj izvedite 3 poskuse s po 30 sekundami za vsak poskus.
After a 4-week treatment-free period, clearance of AKs should be assessed.
Po štiri tedenskem zdravljenju je potrebno pregledati zdravljeno področje, da se ugotovi, ali so AK izginile.
After a 400/100 mg 14C-darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of 14C-darunavir could be retrieved in faeces and urine, respectively.
Po 400/100 mg odmerku s 14C označenega darunavirja z ritonavirjem so v seču izmerili približno 79,5 % danega odmerka darunavirja-14C, v blatu pa 13,9 %.
After a 400/100 mg 14C-darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of 14C-darunavir could be retrieved in faeces and urine, respectively.
Po 400/100 mg odmerku s 14C označenega darunavirja z ritonavirjem so v seču izmerili približno 79,5% danega odmerka darunavirja-14C, v blatu pa 13,9%.
After a 400/100 mg 14C-lopinavir/ritonavir dose, approximately 10.4 ± 2.3% and 82.6 ± 2.5% of an administered dose of 14C-lopinavir can be accounted for in urine and faeces, respectively.
Po odmerku 400 mg/100 mg 14C-lopinavirja/ritonavirja se v urinu izloči približno 10,4  2,3% uporabljenega odmerka 14C-lopinavirja in v blatu 82,6  2,5%.
After a 400/100 mg 14C-lopinavir/ritonavir dose, approximately 10.4  2.3% and 82.6  2.5% of an administered dose of 14C-lopinavir can be accounted for in urine and faeces, respectively.
Po odmerku 400/100 mg 14C-lopinavirja/ritonavirja se v urinu izloči približno 10,4  2,3% uporabljenega odmerka 14C-lopinavirja in v blatu 82,6  2,5%.
After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min.), the results showed a significant 2-fold increase of the exposure (AUC) and half-life (t1/2) as compared to patients with normal renal function.
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina: 20–39 ml/min) so rezultati po 5- dnevnem zdravljenju z repaglinidom (2 mg 3-krat na dan) pokazali pomembno 2-kratno zvečanje izpostavljenosti (AUC) in razpolovnega časa (t1/2) v primerjavi z bolniki z normalnim delovanjem ledvic.
After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min.), the results showed a significant 2-fold increase of the exposure (AUC) and half-life (t1/2) as compared to patients with normal renal function.
Pri bolnikih s hudo okvaro ledvičnega delovanja (očistek kreatinina 20–39 ml/min) so rezultati po 5- dnevnem zdravljenju z repaglinidom (2 mg 3-krat na dan) pokazali pomembno 2-kratno zvečanje izpostavljenosti (AUC) in razpolovnega časa (t1/2) v primerjavi z bolniki z normalnim ledvičnim delovanjem.
After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min.), the results showed a significant 2-fold increase of the exposure (AUC) and half-life (t½) as compared to patients with normal renal function.
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina: 20-39 ml/min) so rezultati po 5-dnevnem zdravljenju z repaglinidom (2 mg 3-krat na dan) pokazali pomembno 2-kratno zvečanje izpostavljenosti (AUC) in razpolovnega časa (t1/2) v primerjavi z bolniki z normalnim delovanjem ledvic.
After a 600 mg abacavir tablet dose, the mean (CV) abacavir Cmax was approximately 4.26 g/ml (28%) and the mean (CV) AUC was 11.95 g.h/ml (21%).
Po 600 mg odmerku abakavirja v obliki tablet je bila srednja (CV) Cmax abakavirja približno 4,26 g/ml (28 %), srednja (CV) AUC pa 11,95 g.h/ml (21 %).
After a few days they may be very tired, and have dark urine, pale faeces, yellowish skin or eyes (jaundice).
Po nekaj dneh so lahko zelo utrujeni, imajo temen urin, svetlo blato, rumenkasto kožo ali oči (zlatenica).
After a few seconds, an aerosol mist will begin to flow into the aerosol chamber of the Zirela Nebuliser Handset.
Po nekaj sekundah bo začel v komoro za aerosol nebulatorja Zirela pršeti aerosol.